IRADIMED CORP
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
IRMD$86.94+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| · · · · · | |||
|---|---|---|---|
| | For the Year Ended | ||
| | December 31, | ||
| · 2023 · 2022 | |||
| Revenue | $65,562,296 | | $53,303,145 |
| Cost of revenue | 15,404,027 | | 12,020,742 |
| Gross profit | 50,158,269 | | 41,282,403 |
| Operating expenses: | | ||
| General and administrative | 15,122,065 | | 10,697,067 |
| Sales and marketing | 12,142,090 | | 12,679,610 |
| Research and development | 2,858,656 | | 2,278,081 |
| Total operating expenses | 30,122,811 | | 25,654,758 |
| Income from operations | 20,035,458 | | 15,627,645 |
| Other income, net | 1,702,798 | | 553,104 |
| Income before provision for income taxes | 21,738,256 | | 16,180,749 |
| Provision for income tax expense | 4,545,480 | | 3,352,262 |
| Net income | $17,192,776 | | $12,828,487 |
| Net income per share: | | ||
| Basic | $1.36 | | $1.02 |
| Diluted | $1.35 | | $1.02 |
| Weighted average shares outstanding: | | ||
| Basic | 12,602,948 | | 12,562,856 |
| Diluted | 12,722,530 | | 12,635,971 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.